RECRUITING

A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.

Conditions

Chikungunya Virus Chikungunya PXVX0317 CHIKV VLP vaccine immunogenicity VIMKUNYA children

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 2 to \<12 years of age.

Official Title

A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children 2 to <12 Years of Age

Quick Facts

Study Start:2025-06-05

Study Completion:2028-12

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT07003984

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:2 Years to 11 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:CHILD

Inclusion Criteria	Exclusion Criteria
1. Males or females between 2 and \<12 years of age at Day 1 (day of vaccination). 2. In general good health, in the opinion of the investigator, based on medical history and physical examination. 3. Able and willing to provide informed assent for study participation and primary caregiver is able and willing to provide informed consent for study participation, in accordance with the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) determination and applicable federal and local regulations and guidelines. 4. Able and willing to complete all scheduled visits and comply with all study procedures.	1. Participation or planned participation in an investigational clinical study (eg, vaccine, drug) within 30 days before Day 1 and for the duration of the study. Note: Participation in an observational study or follow-up phase of a study may be allowed; these instances should be discussed with the sponsor's medical monitor and written agreement obtained prior to enrollment. 2. Current acute illness, with or without fever. 3. Current or recent CHIKV infection indicated by positive immunoglobulin M (IgM) and negative immunoglobulin G (IgG) rapid diagnostic test (RDT) results at screening in the Philippines only; participants in the US will not be tested using the RDT. 4. History of any known or suspected allergy or history of anaphylaxis to any component of the investigational product. 5. History of any known congenital or acquired immunodeficiency or immunosuppressive condition that could impact response to vaccination. 6. Prior receipt or anticipated use of systemic immunomodulatory or immunosuppressive medications from 180 days prior to screening through Day 22. Note: Systemic corticosteroid use at a dose or equivalent dose of 20 mg or greater (≥0.5 mg/kg for children \<40 kg) of prednisone for 14 consecutive days or more within 90 days of screening through Day 22 is exclusionary. The use of inhaled, intranasal, topical, or ocular steroids is allowed. 7. Receipt or anticipated receipt of immunoglobulin from 180 days prior to screening through the duration of the study. 8. Any administration or planned administration of: * A licensed live attenuated vaccine within 28 days before administration of investigational product and until Visit 2 (Day 15 or 22, as applicable) has occurred. * Other licensed (not live) vaccine within 14 days before administration of investigational product and until Visit 2 (Day 15 or 22, as applicable) has occurred. * Another licensed or investigational CHIKV vaccine. 9. Known infection with human immunodeficiency virus, hepatitis C virus (HCV), or hepatitis B virus. Note: Positive anti-HCV antibodies and negative HCV polymerase chain reaction would NOT be exclusionary. Polymerase chain reaction testing will not be performed as part of this protocol. 10. Bleeding disorder or receipt of anticoagulants in the 21 days before Day 1, contraindicating intramuscular vaccination, as judged by the investigator. 11. Receipt or anticipated receipt of blood products from 90 days before Day 1 through the duration of the study. 12. Onset of menarche prior to study vaccination. 13. Planned medical or surgical procedure that could adversely impact the participant's participation or the conduct of the study. 14. Identified as an immediate family member of the investigator or employee with direct involvement in the study. Bavarian Nordic staff members and their families, contractors, agents, business partners, and anyone with a financial interest in the outcome of the study. 15. Any other medical condition, including severe malnutrition, that, in the opinion of the investigator, could adversely impact the participant's participation or conduct of the study.

Inclusion Criteria

Exclusion Criteria

1. Males or females between 2 and \<12 years of age at Day 1 (day of vaccination).
2. In general good health, in the opinion of the investigator, based on medical history and physical examination.
3. Able and willing to provide informed assent for study participation and primary caregiver is able and willing to provide informed consent for study participation, in accordance with the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) determination and applicable federal and local regulations and guidelines.
4. Able and willing to complete all scheduled visits and comply with all study procedures.

1. Participation or planned participation in an investigational clinical study (eg, vaccine, drug) within 30 days before Day 1 and for the duration of the study. Note: Participation in an observational study or follow-up phase of a study may be allowed; these instances should be discussed with the sponsor's medical monitor and written agreement obtained prior to enrollment.
2. Current acute illness, with or without fever.
3. Current or recent CHIKV infection indicated by positive immunoglobulin M (IgM) and negative immunoglobulin G (IgG) rapid diagnostic test (RDT) results at screening in the Philippines only; participants in the US will not be tested using the RDT.
4. History of any known or suspected allergy or history of anaphylaxis to any component of the investigational product.
5. History of any known congenital or acquired immunodeficiency or immunosuppressive condition that could impact response to vaccination.
6. Prior receipt or anticipated use of systemic immunomodulatory or immunosuppressive medications from 180 days prior to screening through Day 22. Note: Systemic corticosteroid use at a dose or equivalent dose of 20 mg or greater (≥0.5 mg/kg for children \<40 kg) of prednisone for 14 consecutive days or more within 90 days of screening through Day 22 is exclusionary. The use of inhaled, intranasal, topical, or ocular steroids is allowed.
7. Receipt or anticipated receipt of immunoglobulin from 180 days prior to screening through the duration of the study.
8. Any administration or planned administration of:
* A licensed live attenuated vaccine within 28 days before administration of investigational product and until Visit 2 (Day 15 or 22, as applicable) has occurred.
* Other licensed (not live) vaccine within 14 days before administration of investigational product and until Visit 2 (Day 15 or 22, as applicable) has occurred.
* Another licensed or investigational CHIKV vaccine.
9. Known infection with human immunodeficiency virus, hepatitis C virus (HCV), or hepatitis B virus. Note: Positive anti-HCV antibodies and negative HCV polymerase chain reaction would NOT be exclusionary. Polymerase chain reaction testing will not be performed as part of this protocol.
10. Bleeding disorder or receipt of anticoagulants in the 21 days before Day 1, contraindicating intramuscular vaccination, as judged by the investigator.
11. Receipt or anticipated receipt of blood products from 90 days before Day 1 through the duration of the study.
12. Onset of menarche prior to study vaccination.
13. Planned medical or surgical procedure that could adversely impact the participant's participation or the conduct of the study.
14. Identified as an immediate family member of the investigator or employee with direct involvement in the study. Bavarian Nordic staff members and their families, contractors, agents, business partners, and anyone with a financial interest in the outcome of the study.
15. Any other medical condition, including severe malnutrition, that, in the opinion of the investigator, could adversely impact the participant's participation or conduct of the study.

Contacts and Locations

Study Contact

Priya Uppin

CONTACT

844-422-8274

info@bavarian-nordic.com

Faye Cross

CONTACT

info@bavarian-nordic.com

Principal Investigator

Patrick Ajiboye, MD

STUDY_DIRECTOR

Bavarian Nordic A/S

Study Locations (Sites)

ARK Clinical Research, LLC

Fountain Valley, California, 92708

United States

Emerson Clinical Research Institute- DC

Washington, District of Columbia, 20009

United States

Acevedo Clinical Research

Miami, Florida, 33142

United States

Hope Research Network

Miami, Florida, 33166

United States

Velocity Clinical Research-Omaha

Omaha, Nebraska, 68134

United States

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229

United States

KidCare Pediatrics

Beaumont, Texas, 77706

United States

Velocity Clinical Research - Salt Lake City

West Jordan, Utah, 84088

United States

Collaborators and Investigators

Sponsor: Bavarian Nordic

Patrick Ajiboye, MD, STUDY_DIRECTOR, Bavarian Nordic A/S

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-06-05

Study Completion Date2028-12

Study Record Updates

Study Start Date2025-06-05

Study Completion Date2028-12

Terms related to this study

Keywords Provided by Researchers

Chikungunya
PXVX0317
CHIKV VLP
vaccine
immunogenicity
VIMKUNYA
children

Additional Relevant MeSH Terms

Chikungunya Virus